Go Back Menu
Close
Products
No.1 in prescriptions and still
growing faster
Mankind's prescription portfolio cover both acute and chronic therapeutic areas
The diversified portfolio puts a de-risked strategy in place across booming segments. There has been a conscious move to focus on the chronic segment in the recent past, with the share rising to 36% (FY24) compared to 18% (FY18). Our growth in prescriptions has consistently outpaced the Indian pharma market growth rate.
#1
in prescriptions over
7 years
7 years
#2
in covered market in
FY23
FY23
#3
Rank by
volume
volume
#4
Rank by
value
value
Announcement
GST Benefit to Consumers – New MRPs from 22nd Sept
In response to the recent GST rate reduction, we have reduced MRPs of our products effective 22nd September 2025. This move not only aligns with regulatory changes but also reflects our commitment to making quality healthcare more affordable and accessible.
Our Products
Our portfolio of500+ products comprises a broad range of formulations across various acute and chronic therapeutic areas.
Anti-infectives
15%
Anti-infectives portfolio share in domestic sales
cardiovascular
15%
Cardiovascular portfolio share in domestic sales
Gastrointestinal
10%
Gastrointestinal portfolio share in domestic sales
Respiratory
9%
Respiratory portfolio share in domestic sales
Vitamins / Minerals / Nutrients
8%
VMN portfolio share in domestic sales
Anti-Diabetic
9%
Anti-diabetic portfolio share in domestic sales
Gynaecology
8%
Gynaecology portfolio share in our domestic sales
Dermatology
5%
Dermatology portfolio share in domestic sales
Pain / Analgesics
4%
Pain / Analgesics portfolio share in domestic sales
Neuro / CNS
3%
Neuro/CNS portfolio share in domestic sales
